Concepedia

Jeffrey Riesmeyer

JR

Statistics

Publications

5

Citations

7.6K

H-Index

5

Active since

2007

Affiliations

Eli Lilly (United States)(Current)

The University of Adelaide

Harvard University

Cleveland Clinic

Sorbonne Université

Jeffrey Riesmeyer is an author at Eli Lilly (United States) specializing in atherosclerosis, vascular biology, and medicine.

Top concepts

Publications per year

2007–2020

5

Publications

5

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2007 · 6.7K citations · Full text

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

A. Michael Lincoff, Stephen J. Nicholls, Jeffrey Riesmeyer et al. · New England Journal of Medicine · 2017 · 768 citations · Full text

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

Stephen J. Nicholls, A. Michael Lincoff, Philip J. Barter et al. · American Heart Journal · 2015 · 90 citations

, , +10

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

Venu Menon, Anirudh Kumar, Divyang Patel et al. · BMJ Open Diabetes Research & Care · 2020 · 27 citations · Full text

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

A. Michael Lincoff, Stephen J. Nicholls, Jeffrey Riesmeyer et al. · Journal of Vascular Surgery · 2017 · 10 citations

, , +8

1–5 of 5